Background: We have recently shown that the transjugular intrahepatic portosystemic shunt (TIPS) is more effective than paracentesis in the treatment of cirrhotic patients with severe ascites and can prolong survival in selected patients. Although an improved quality of life (QOL) has been suggested in these patients after the TIPS procedure, so far there are no data available to substantiate this assumption. Therefore, the aim of this study was to determine the effect of TIPS on the QOL in cirrhotic patients with refractory or recidivant ascites. Methods: 21 cirrhotic patients who underwent TIPS for refractory or recidivant ascites were investigated. All patients were pretreated with repeated paracentesis for at least 1 year. Before the procedure and at 3 and 6 months during follow-up, the patients themselves rated QOL, fatigue and physical performance on a visual analogue scale (range 0–100). Furthermore, QOL was determined by the QOL index (range 0–10) according to Spitzer. Results: Patients’ rating of the QOL on the visual analogue scale significantly increased from 35 ± 25 (baseline) to 64 ± 28 (3 months), and 66 ± 24 (6 months; p = 0.02). Similarly, the QOL index significantly increased from 6.9 ± 2.0 (baseline) to 8.3 ± 2.1 (3 months), and 8.6 ± 1.7 (6 months; p < 0.001). The increase of QOL was more pronounced in patients with complete response to TIPS. Conclusions: We demonstrate that TIPS for refractory or recidivant ascites improves the QOL in patients with cirrhosis. Our data indicates that this improvement is dependent on the response to therapy.

Gerbes AL, G&uuml;lberg V, Waggershauser T, Holl J, Reiser M: Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis of the liver: Comparison of patients with ascites and refractory ascites and without ascites. Hepatology 1998;28:683&ndash;688.
Michl P, G&uuml;lberg V, Bilzer M, Waggershauser T, Reiser M, Gerbes AL: Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: Effects in patients with organic or functional renal failure. Scand J Gastroenterol 2000;35:654&ndash;658.
Ochs A, R&ouml;ssle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, Huonker M, Langer M, Blum HE: The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995;332:1192&ndash;1197.
R&ouml;ssle M, Ochs A, G&uuml;lberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL: A comparison of paracentesis and the intrahepatic portosystemic shunt procedure in patients with ascites. N Engl J Med 2000;342:1701&ndash;1707.
R&ouml;ssle M, Siegerstetter V, Huber M, Ochs A: The first decade of the transjugular intrahepatic portosystemic shunt: State of the art. Liver 1998;18:73&ndash;89.
Nazarian GK, Ferral H, Bjarnason H, Castaneda-Zuniga WR Rank JM, Bernadas CA, Hunter DW: Effect of transjugular intrahepatic portosystemic shunt on quality of life. Am J Roentgenol 1996;167:963&ndash;969.
Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Sch&ouml;lmerich J: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164&ndash;176.
Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Sheperd R, Battista RN, Catchlove BR: Measuring the quality of life of cancer patients. J Chron Dis 1981;34:585&ndash;597.
Sherlock S, Dooley J: Hepatic encephalopathy; in Sherlock S, Dooley J (eds): Diseases of the liver and biliary system, ed 10. Oxford, Blackwell,1997, pp 87&ndash;102.
Karnofsky DA, Burchenal JH: Clinical evaluation of chemotherapeutic agents in cancer; in McLeod CM (ed): Evaluation of Chemotherapeutic Agents. New York, Columbia University Press, 1949, pp 191&ndash;205.
Grieco A, Long CJ: Investigation of the Karnofsky Performance Status &ndash; A measure of quality of life. Health Psychol 1984;3:129&ndash;142.
Schipper H: Why measure quality of life? Can Med Assoc J 1983;128:1367&ndash;1370.
Gough IR, Furnival CM, Schilder L, Grove W: Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983;19:1161&ndash;1165.
Nolte W, Wiltfang J, Schindler C, M&uuml;nke H, Unterberg K, Zumhasch U, Figulla HR, Werner G, Hartmann H, Ramadori G: Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Clinical, laboratory, psychometric and electroencephalographic investigations. Hepatology 1998;28:1215&ndash;1225.
Langer B, Taylor BR, Mackenzie DR, Gilas T, Stone RM, Blendis L: Further report of a prospective randomized controlled trial comparing distal splenorenal shunt with end-to-side portacaval shunt: An analysis of encephalopathy, survival and quality of life. Gastroenterology 1985;88:424&ndash;429.
You do not currently have access to this content.